Navigation Links
Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
Date:12/7/2011

cutive Officer of Silence, said: "We are very pleased with the outcome of this oral opposition hearing, which has upheld the key part of our claims in this granted patent. In addition to this granted patent on PKN3, our Atu027 clinical program is also protected by further granted patents and patent applications for the formulation with Silence's AtuPLEX™ delivery technology, the sequence of the siRNA molecules and the AtuRNAi chemistry used in the sequence. Our Atu027 trial continues as planned with two patients now recruited for cohort 10 out of 11 dose levels, and we are still on track to complete recruitment in early 2012 with results reported by mid-2012."

Notes for editors                  

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery o
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Provides Corporate and Development Update
2. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
3. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
4. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
5. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
8. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
9. Silence Therapeutics Appoints New Vice President of Research
10. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
11. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... FL (PRWEB) , ... August 31, 2015 , ... ... bring together the world's most successful food and beverage processors, equipment manufacturers and ... competencies in product inspection and industrial weighing and formulation for manufacturers of bakery ...
(Date:8/30/2015)... , August 31, 2015 , ... Frau   für chirurgische   Behandlung     ... 7-90   werden für eine   verheerende   Geburtsverletzung ... behandeln und die Anzahl ausgebildeter Chirurgen in Kenia bis ... gab heute bekannt, dass  Action on Fistula  seit ihrem ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ... With a focus on evidence-based research and clinical application, the event gathered industry ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue ... healing of an otherwise non-healing surgical knee wound. , The case involved a ...
Breaking Biology Technology:METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... CANNES, France, June 24, 2011 Mediabrands, IPG ... Cannes Lions International Advertising Festival, the results of ... by MIT, Affectiva is able to record and ... points, correlating to an individual,s facial features are ...
... June 24, 2011 Amgen (NASDAQ: AMGN ... for Human Use (CHMP) of the European Medicines Agency ... (panitumumab) be approved for use in the European Union ... second-line in combination with FOLFIRI in patients who have ...
... ,   Coventry Building ... Legion by launching Poppy Online,Saver , a market-leading ... Saver is an ,easy access internet savings account ... each year, with,further withdrawals possible with the loss of ...
Cached Biology Technology:The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 2Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 4Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 5Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 6Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 7Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 8Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 9Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 10Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 2Coventry Launches Market Leading Online Savings Account With Added Poppy Appeal 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... study reports for the first time that a less-virulent strain ... The research appears in the October 1 issue of ... the species barrier is an important step in the development ... focused on the ability of highly pathogenic strains, such as ...
... will lead a new $52.7 million research program that ... life's most fundamental processes and point the way to ... Gaetano Montelione, the Northeast Structural Genomics Consortium (NESG) will ... the largest in Rutgers' history, will reinforce our dynamic ...
... Using a newly released method to analyze functional ... demonstrated that the interconnections between different parts of ... and other findings answer longstanding debates about how ... They are presented in the current (June 1) ...
Cached Biology News:Eating, body weight regulated by specific neurons 2Rutgers to lead $52.7 million protein research program 2Rutgers to lead $52.7 million protein research program 3Rutgers to lead $52.7 million protein research program 4Brain networks change according to cognitive task 2Brain networks change according to cognitive task 3
... catalyzes the degradation of single-stranded DNA and ... While the nuclease prefers ssDNA over dsDNA ... enzyme degrades double-stranded DNA from both ends ... for transcript mapping studies (3,4), for flushing ...
... The S.c. EasyComp Transformation Kit is ... Saccharomyces cerevisiae cells. Advantages over commonly ... formation or LiCl methods include:- Cells can ... 30 minutes - Competent cell preparation and ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
Biology Products: